The phase II clinical trial was designed to evaluate the efficacy, safety, and immunogenicity of the vaccine that combined irradiated allogeneic lung adenocarcinoma cells with a bystander K562 cell line, transfected with hCD40L and hGM-CSF. Here, CD40LG is linked to lung adenocarcinoma.